摘要
目的:探讨药物相关分子靶标检测在原发性肝癌切除术后预防性肝动脉介入化疗栓塞(transcatheter arterial chemoembolization,TACE)中的临床价值.方法:将原发性肝癌切除并在术后行预防性TACE的92例患者分为分子靶标检测筛选化疗药物组(观察组,n=50)和经验选用化疗药物组(对照组,n=42),比较两组患者1年复发率、TACE后不良反应发生情况,应用KaplanMeier法比较无瘤生存期,绘制无瘤生存曲线并进行Log-rank检验.结果:观察组1年复发率明显低于对照组(χ2=4.422,P=0.035);观察组平均无瘤生存期明显优于对照组(t=3.081,P=0.003).两组无瘤生存曲线差异有统计学意义(χ2=5.99,P=0.014);观察组TACE后恶心呕吐、腹泻、白细胞计数下降发生率低于对照组(P<0.05),两组发热发生率差异无统计学意义(χ2=0.091,P=0.763).结论:原发性肝癌切除术后依据分子靶标检测筛选化疗药物行预防性TACE可明显延缓肿瘤复发、延长无瘤生存期、减少不良反应发生.
AIM： To investigate the value of detection of molecules associated with drug sensitivity in preventive transcatheter arterial chemoembolization （TACE） for patients with hepatocellular carcinoma （HCC） after hepatectomy.
METHODS： A total of 92 patients with HCC receiving preventive TACE within three months after hepatectomy were divided into an observation group （n = 50） and a control group （n = 42）. In the observation group, chemotheraputic agents were selected based on the detection of molecules associated with drug sensitivity, while chemotheraputic agents were chosen empirically in the control group. The one-year recurrence rate, side effects of TACE and disease-free survival time were compared between the two groups.
RESULTS： The one-year recurrence rate in the observation group was lower than that of the control group （χ^2 = 4.422, P = 0.035）. The difference in disease-free survival time between the two groups was of statistical significance （t = 3.081, P = 0.003）. The disease-free survival curve of the observation group differed from that of the control group （2 = 5.99, P = 0.014）.The incidence rates of nausea, emesis, diarrhea, and leukopenia in the observation group after TACE were significantly lower than those of the control group （P 〈 0.05）. The difference in the incidence rate of fever after TACE had no statistical difference between the two groups （χ^2 = 0.091, P = 0.763）. CONCLUSION： Selection of chemotheraputic agents based on detection of molecules can delay recurrence, prolong disease-free survival time and reduce the incidence of side effects after TACE in patients with HCC after hepatectomy.
出处
《世界华人消化杂志》
CAS
2015年第35期5693-5698,共6页
World Chinese Journal of Digestology
基金
卫生部医药卫生科技发展研究中心基金资助项目
No.W2012FZ065~~
关键词
原发性肝癌
药物相关分子靶标检测
肝动脉介入化疗栓塞
个体化化疗
1年复发率
无瘤生存期
Hepatocellular carcinoma
Moleculesassociated with drug sensitivity
Transcatheterarterial chemoembolization
Individualizedchemotherapy
One-year recurrence rate
Diseasefree survival time
